More early Phase I and II studies will be conducted to investigate the presence of ethnic-specific determinants that confer interethnic differences in sensitivity and toxicity to chemotherapy and targeted therapy. The results from such studies will be used in the design of international clinical trials. For an example, based on the results of the Phase I study of ARQ 197 in Japanese patients described previously, east Asian patients will be screened for CYP2C19 in a Phase III study of erlotinib with or without ARQ 197. In an ongoing Phase III study comparing the efficacy of crizotinib versus pemetrexed and platinum (the PROFILE 1014 study), based on the differences in the PKs of crizotinib between Asians and non-Asians described previously, one of the stratification factors at randomization is ethnicity. Current efforts are underway to individualise lung cancer treatment based on genetic make-up of the patient's tumor;[65,67] whether ethnicity will remain an important factor in this setting remains unknown.
Future Oncol. 2012;8(4):451-462. © 2012 Future Medicine Ltd.